ILMN Stock Recent News

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Illumina (ILMN) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.32 per share a year ago.

Gene sequencing machine maker Illumina on Tuesday forecast 2024 sales from its core segment to decline, a sign that subdued demand for its instruments used in genetic tests could extend further into the year.

Core Illumina revenue of $1.09 billion for Q2 2024, down 6% from Q2 2023 (down 6% on a constant currency basis) and up 3% from Q1 2024 Core Illumina GAAP operating margin of 40.5% and non-GAAP operating margin of 22.2% for Q2 2024 Core Illumina GAAP diluted earnings per share of $0.41 and non-GAAP diluted earnings per share of $1.09 for Q2 2024 Lowered fiscal year 2024 Core Illumina revenue guidance to decline 2% to 3% (down 1.5% to 2.5% in constant currency) from 2023 Raised Core Illumina non-GAAP operating margin guidance to a range of 20.5% to 21% for fiscal year 2024 Introducing guidance for Core Illumina non-GAAP diluted earnings per share in the range of $3.80 to $3.95 for fiscal year 2024 On June 24, 2024, we completed the spin-off of GRAIL into a new public company SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2024, which include the consolidated fi

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Delivers Illumina's flagship oncology products on its most powerful sequencers to enable comprehensive genomic profiling at greater scale and at lower overall costs for customers SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has expanded its oncology menu for NovaSeq™ X Series customers. The company began offering the newly verified high-throughput version of TruSight™ Oncology 500 (TSO 500 HT), and the latest version of its distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), in recent months.

Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The consensus price target hints at a 27% upside potential for Illumina (ILMN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.